Mereo BioPharma Group plc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
MREO$0.30+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(29,466) | $(42,220) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 4,924 | 4,768 |
| Depreciation | 171 | 181 |
| Amortization of intangible assets | 395 | — |
| Amortization of operating lease right-of-use assets | 495 | 708 |
| Change in fair value of warrants | (245) | (9,286) |
| Interest income | (102) | — |
| Interest expense | 1,942 | 4,103 |
| Foreign currency transaction loss/(gain) | 2,347 | (2,723) |
| Other (income)/expenses | — | (2,000) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 502 | 532 |
| Research and development incentives receivable | 456 | (3,467) |
| Accounts payable | (1,263) | 617 |
| Accrued expenses and other liabilities | (710) | 844 |
| Operating lease liabilities | (578) | (878) |
| Net cash used in operating activities | (21,132) | (48,821) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | — | (13) |
| Proceeds from out-licensing | — | 2,000 |
| Purchase of intangible assets | (419) | — |
| Net cash provided by/(used in) investing activities | (419) | 1,987 |
| Cash flows from financing activities | ||
| Proceeds from TAP agreement | 100 | 200 |
| Proceeds from issuance of ordinary shares | 11,605 | — |
| Transaction costs on issuance of ordinary shares | (511) | — |
| Transaction costs on convertible loan notes | (33) | — |
| Redemption of convertible loan notes | (3,188) | — |
| Net cash provided by financing activities | 7,973 | 200 |
| Decrease in cash and cash equivalents | (13,579) | (46,634) |
| Cash and cash equivalents at January 1 | 68,182 | 127,398 |
| Effect of exchange rate changes | 2,818 | (12,582) |
| Cash and cash equivalents at December 31 | $57,421 | $68,182 |
| Supplemental disclosure | ||
| Cash paid for interest | 884 | 24 |
| Cash (received)/paid for income taxes | (1,337) | 1,882 |
| Cash paid for the amounts included in the measurement of operating lease liabilities | 759 | 1,153 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Conversion of notes into ordinary shares | 5,318 | 3,428 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.